2021年美国风湿病学会幼年特发性关节炎治疗指南:少关节炎、颞下颌关节炎及全身型幼年特发性关节炎的治疗路径
该指南由美国风湿病学会制定,采用PICO问题、系统文献综述和GRADE方法,针对少关节炎、颞下颌关节炎及伴或不伴巨噬细胞活化综合征的全身型幼年特发性关节炎提供初始与后续治疗及减停推荐。所有推荐证据质量均为低或极低,超过半数推荐为条件性推荐。
要点
- 推荐基于临床表型而非特定分类标准,涵盖少关节炎、颞下颌关节炎和全身型幼年特发性关节炎。
- 所有推荐证据质量均为低或极低,超过半数推荐为条件性推荐。
- 指南补充2019年ACR幼年特发性关节炎和葡萄膜炎指南,支持临床决策。
核心结论
- 该指南补充2019年美国风湿病学会幼年特发性关节炎和葡萄膜炎指南,后者涵盖多关节炎、骶髂关节炎、附着点炎和葡萄膜炎。
- 指南作为工具支持临床医生、患者和照护者决策,考虑关节及非关节表现严重度和患者生活质量。
- 尽管证据质量普遍低且许多推荐为条件性推荐,照护者和患者参与决策过程增强了指南的相关性和适用性。
- 这些是推荐,临床决策应始终由治疗临床医生和患者/照护者做出。
研究设计与样本
- 美国风湿病学会制定,开发临床相关PICO问题,进行系统文献综述,采用GRADE方法评级证据质量(高、中、低或极低)。
- 投票小组包括临床医生和患者/照护者,就推荐方向(支持或反对)和强度(强或条件性)达成共识。
主要发现
- 与2019年发表的推荐类似,这些幼年特发性关节炎推荐基于临床表型而非特定分类标准。
- 指南提供少关节炎、颞下颌关节炎和全身型幼年特发性关节炎的初始及后续治疗推荐,以及无活动性全身型幼年特发性关节炎的减停治疗推荐。
- 讨论疾病管理其他方面,包括影响治疗选择和药物减量的因素。
- 所有推荐证据质量评级为低或极低,因此超过半数推荐为条件性推荐。
关键数值与推荐
- 所有推荐证据质量评级为低或极低。
- 超过半数的推荐为条件性推荐。
临床怎么用
- 指南作为工具支持临床医生、患者和照护者在决策中使用。
- 推荐考虑关节及非关节表现严重度和患者生活质量。
- 临床决策应始终由治疗临床医生和患者/照护者做出。
局限性
- 所有推荐证据质量评级为低或极低。
- 超过半数的推荐为条件性推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide updated guidelines for pharmacologic management of juvenile idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) arthritis, and systemic JIA with and without macrophage activation syndrome. Recommendations regarding tapering and discontinuing treatment in inactive systemic JIA are also provided. METHODS: We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. RESULTS: Similar to those published in 2019, these JIA recommendations are based on clinical phenotypes of JIA, rather than a specific classification schema. This guideline provides recommendations for initial and subsequent treatment of JIA with oligoarthritis, TMJ arthritis, and systemic JIA as well as for tapering and discontinuing treatment in subjects with inactive systemic JIA. Other aspects of disease management, including factors that influence treatment choice and medication tapering, are discussed. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional. CONCLUSION: This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis. It serves as a tool to support clinicians, patients, and caregivers in decision-making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision-making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.
引用
- Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022. PMID: 35233993. doi:10.1002/art.42037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。